1 / 6

TREND TODAY REPORT-MONEY CLASSIC RESEARCH

cation course is designed to give maximum hands on practice which is the biggest strength of this course. One of the specialty of this course is to t

moneyclassic
Download Presentation

TREND TODAY REPORT-MONEY CLASSIC RESEARCH

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. 22-JAN-16

  2. Husains MARKET WRAP The market has ended lower once again. The Sensex ended below 24000 for first time since May 2014. The 30-share index was down 99.83 points or 0.4 percent at 23962.21 and the Nifty slipped 32.50 points or 0.4 percent at 7276.80. About 1289 shares advanced, 1301 shares declined and 184 shares were unchanged. Axis Bank, Tata Steel, Wipro, SBI and Infosys were top gainers while Tata Motors, Dr Reddy's Labs, Maruti, Coal India and ONGC were losers in the Sensex. BROAD MARKET INDICES INDEX P. CLOSE OPEN HIGH LOW CLOSE %CHANGE NIFTY 50 7,309.30 7,376.65 7,398.70 7,250.00 7,276.80 -0.44 NIFTY NEXT 50 17,938.05 18,124.20 18,224.90 17,673.85 17,715.55 -1.24 NIFTY100 LIQ15 2,726.45 2,756.25 2,776.80 2,706.40 2,735.35 0.33 NIFTY MIDCAP 50 2,928.90 2,961.40 2,995.65 2,904.25 2,944.95 0.55 Contact No. +91-903-977-7700 www.moneyclassicresearch.com

  3. ASIAN INDEXES INDEX OPEN HIGH LOW CLOSE %CHANGE NIKKEI 225 16,466.86 16,734.58 16,017.26 16,017.26 -2.49 HANG SENG 19,079.13 19,238.27 18,534.30 18,542.15 -1.86 TAIWAN 7,713.17 7,748.37 7,664.01 7,664.01 -0.46 SSE 2,934.39 2,998.79 2,880.08 2,880.80 -3.33 INDIAN MAJOR SECTORAL INDICES INDEX P. CLOSE OPEN HIGH LOW CURRENT %CHANGE NIFTY BANK 14,935.50 15,132.20 15,364.60 14,918.15 15,101.20 1.11 NIFTY FIN SERVICE 6,279.85 6,356.20 6,416.25 6,260.20 6,317.60 0.60 NIFTY PHARMA 11,133.65 11,241.00 11,243.95 10,825.50 10,876.60 -2.31 NIFTY IT 10,910.50 10,957.95 10,994.90 10,893.35 10,934.30 0.22 Contact No. +91-903-977-7700 www.moneyclassicresearch.com

  4. STOCK UPDATE Glenmark Pharma Gets USFDA Nod For Two Generic Drugs Glenmark Pharma today said it has received final approval from the USFDA to manufacture and market Potassium Chloride extended release capsules and oral contraceptive Norethindrone Acetate and Ethinyl Estradiol tablets in the American market. Quoting IMS data, Glenmark Pharma said the approved product has an estimated market size of USD 74.1 million for the 12 months ended November 2015.The Company has also received approval for Norethindrone Acetate and Ethinyl Estradiol tablets. Glenmark Pharma's current portfolio consists of 62 ANDAs pending approvals from the US FDA and 106 products authorized for distribution in the US. Contact No. +91-903-977-7700 www.moneyclassicresearch.com

  5. Natco Pharma Signs Agreement for Manufacturing, Sale of Hepatitis C Drug Natco Pharma has signed a non-exclusive licensing agreement with the Medicines Patent. Pool (MPP) and Bristol-Myers Squibb to manufacture and sell generic versions of Daclatasvir, used for the treatment of chronic hepatitis C. Compared to other treatment options, this combination not only increases the cure rate, but is also regarded as a valuable treatment option in some of the difficult-to-treat HCV patient subsets. "This agreement allows Natco to expand access to these chronic hepatitis C medicines in 112 developing countries. Under the licence, Natco can set its own price for the generic products it produces," it said. Shares of Natco Pharma were trading 4.06 per cent up at Rs 527.50 apiece on BSE. Contact No. +91-903-977-7700 www.moneyclassicresearch.com

More Related